Exicure, Inc. Announces Participation in Upcoming Conferences

Rhea-AI Summary

Exicure, Inc. (NASDAQ: XCUR) has announced CEO David Giljohann's participation in two upcoming conferences. The BIO Digital 2021 conference will feature a corporate update presentation on June 10, 2021, available for on-demand viewing. The BMO Biopharma Day will include a rare disease panel on June 22, 2021, streamed live at 10:30 AM ET. Exicure focuses on developing innovative therapeutics leveraging its Spherical Nucleic Acid technology, targeting conditions such as Friedreich’s ataxia and advanced solid tumors.

Exicure, Inc.^® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that CEO David Giljohann will participate in the following upcoming conferences:

BIO Digital 2021
Format: Corporate update presentation
Date: June 10, 2021
Time: 7:00 AM ET
Location: The presentation will be available to registered conference attendees for on-demand viewing beginning June 10, 2021 at 7:00 AM ET via the virtual conference link and will be archived for 90 days on Exicure’s website following the conference.

BMO Biopharma Day: Spotlight on Rare Disease and Ophthalmology
Format: Rare Disease Panel: Central Nervous System
Date: June 22, 2021
Time: 10:30 AM ET
Location: The panel discussion will be available for live streaming to conference attendees at the virtual conference link.

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN a lipid-nanoparticle SNA–based therapeutic candidate, for the intrathecal treatment of Friedreich’s ataxia (FA). Exicure’s therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based in Chicago, IL and in Cambridge, MA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005227/en/

FAQ

What is the schedule for Exicure's upcoming conferences in June 2021?

Exicure's CEO will present at BIO Digital 2021 on June 10, 2021, and participate in the BMO Biopharma Day on June 22, 2021.

What is Exicure's focus in biotechnology?

Exicure is a clinical-stage biotechnology company focused on developing therapeutics for neurology, immuno-oncology, and inflammatory diseases using Spherical Nucleic Acid technology.

What therapeutic candidate is Exicure developing for Friedreich’s ataxia?

Exicure is developing XCUR-FXN, a lipid-nanoparticle SNA-based therapeutic candidate for the intrathecal treatment of Friedreich’s ataxia.

In which clinical trial is Exicure's cavrotolimod involved?

Cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial for patients with advanced solid tumors.

Where can I find Exicure's conference presentations after the events?

Presentations from the BIO Digital 2021 conference will be archived for 90 days on Exicure's website.